ICSBP Antibody (F-9): sc-365041

ICSBP Antibody (F-9) is a mouse monoclonal IgG2a antibody that detects ICSBP (Interferon consensus sequence-binding protein, also known as Interferon regulatory factor 8; IRF-8) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). ICSBP plays a crucial role as a transcription factor in the regulation of immune responses, particularly in the signaling pathways mediated by interferon-gamma (IFN-γ) during the differentiation of dendritic cells and macrophages. ICSBP′s ability to interact with TRAF6, specifically between amino acid residues 356 and 305, is significant as ICSBP modulates Toll-like receptor (TLR) signaling, thereby contributing to the intricate cross-talk between IFN-γ and TLR pathways, which is essential for effective immune responses. Additionally, ICSBP antagonizes Bcr/Abl by downregulating Bcl-2, further highlighting ICSBP′s importance in cellular signaling and apoptosis regulation. As a member of the interferon regulatory factor (IRF) family, which includes IRF-1, IRF-2, and ISGF-3, ICSBP features a conserved DNA-binding domain in its N-terminal region and a divergent C-terminal regulatory domain, allowing ICSBP to bind to the interferon-stimulated response element (ISRE) and regulate the expression of IFN-α and IFN-β, thus playing a pivotal role in the immune response and inflammation.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ICSBP Antibody (F-9) References:

1. ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages.  |  Tamura, T., et al. 2000. Immunity. 13: 155-65. PMID: 10981959
2. Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion.  |  Rosenbauer, F., et al. 2002. EMBO J. 21: 211-20. PMID: 11823414
3. ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells.  |  Tamura, T., et al. 2003. Blood. 102: 4547-54. PMID: 12933588
4. ICSBP/IRF-8 differentially regulates antigen uptake during dendritic-cell development and affects antigen presentation to CD4+ T cells.  |  Mattei, F., et al. 2006. Blood. 108: 609-17. PMID: 16569763
5. The interferon consensus sequence-binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells.  |  Huang, W., et al. 2008. J Biol Chem. 283: 7921-35. PMID: 18195016
6. The interferon consensus sequence binding protein (ICSBP/IRF8) activates transcription of the FANCF gene during myeloid differentiation.  |  Saberwal, G., et al. 2009. J Biol Chem. 284: 33242-54. PMID: 19801548
7. Interferon consensus sequence-binding protein (ICSBP) promotes epithelial-to-mesenchymal transition (EMT)-like phenomena, cell-motility, and invasion via TGF-β signaling in U2OS cells.  |  Sung, JY., et al. 2014. Cell Death Dis. 5: e1224. PMID: 24832596
8. ICSBP-induced PD-L1 enhances osteosarcoma cell growth.  |  Sung, JY., et al. 2022. Front Oncol. 12: 918216. PMID: 36249036

The preferred ICSBP antibody is ICSBP Antibody (E-9): sc-365042.